Harrow makes treatments for eye conditions such as dry eye disease and cataracts, and products for surgical procedures.

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

A decades-old way to bridge buyers and sellers on price, contingent value rights have recently seen an uptick in use due to a ...

Shares of Regeneron Pharmaceuticals ( REGN 0.56%), a biotech giant, have been southbound over the past two years as the ...

July 25 (Reuters) - Danaher Corp (DHR.N), opens new tab on Tuesday cut its annual sales growth forecast for a second straight quarter, signaling that funding crunch in the drug development market was ...

Net Sales at Rs 13.02 crore in September 2025 up 8.16% from Rs. 12.04 crore in September 2024. Quarterly Net Profit at Rs. 0.87 crore in September 2025 down 83.64% from Rs. 5.31 crore in September ...

Theratechnologies’ R&D staff is bearing the brunt of its commercial failings. With sales falling short of expectations, the biotech is reducing its R&D head count and narrowing its focus to lower ...

Quarterly Net Profit at Rs. 62.90 crore in September 2025 down 36.27% from Rs. 98.70 crore in September 2024. EBITDA stands at Rs. 103.97 crore in September 2025 down 29.13% from Rs. 146.70 crore in ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our full ...

Newcells Biotech (“Newcells”), a leading drug discovery partner specializing in developing in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today ...